Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: A phase I/II randomized control trial
Shaukat Ali, Syed Muneeb Uddin, Elisha Shalim, et al.
EClinicalMedicine (2021) Vol. 36, pp. 100926-100926
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Antibody and cellular therapies for treatment of covid-19: a living systematic review and network meta-analysis
Reed Siemieniuk, Jessica Bartoszko, Juan Pablo Díaz Martinez, et al.
BMJ (2021), pp. n2231-n2231
Open Access | Times Cited: 75
Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial
Mark N. Polizzotto, Jacqueline Nordwall, Abdel G. Babiker, et al.
The Lancet (2022) Vol. 399, Iss. 10324, pp. 530-540
Open Access | Times Cited: 66
Mortality Rates Among Hospitalized Patients With COVID-19 Treated With Convalescent Plasma: A Systematic Review and Meta-Analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
Mayo Clinic Proceedings Innovations Quality & Outcomes (2023) Vol. 7, Iss. 5, pp. 499-513
Open Access | Times Cited: 30
Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Chenyang Zhang, Huaqing Jin, Yi Feng Wen, et al.
Frontiers in Public Health (2021) Vol. 9
Open Access | Times Cited: 38
Differential efficacy and safety of anti-SARS-CoV-2 antibody therapies for the management of COVID-19: a systematic review and network meta-analysis
Jiawen Deng, Kiyan Heybati, Harikrishnaa Ba Ramaraju, et al.
Infection (2022) Vol. 51, Iss. 1, pp. 21-35
Open Access | Times Cited: 26
Hyperimmune immunoglobulin for people with COVID-19
Catherine Kimber, Sarah J Valk, Khai Li Chai, et al.
Cochrane library (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 16
Hyperimmune Plasma and Immunoglobulins against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
Life (2024) Vol. 14, Iss. 2, pp. 214-214
Open Access | Times Cited: 5
Intravenous immunoglobulin (IVIg) therapy in hospitalised adult COVID‐19 patients: A systematic review and meta‐analysis
Robert Marčec, Vinko Michael Dodig, Igor Radanović, et al.
Reviews in Medical Virology (2022) Vol. 32, Iss. 6
Open Access | Times Cited: 21
Nucleocapsid-specific antibody function is associated with therapeutic benefits from COVID-19 convalescent plasma therapy
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
Cell Reports Medicine (2022) Vol. 3, Iss. 11, pp. 100811-100811
Open Access | Times Cited: 21
Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Mingtao Liu, Hui Gan, Zhiman Liang, et al.
Frontiers in Microbiology (2023) Vol. 14
Open Access | Times Cited: 13
Benefits of high-dose intravenous immunoglobulin on mortality in patients with severe COVID-19: An updated systematic review and meta-analysis
Xiaosheng Liu, Yuelun Zhang, Lianfeng Lu, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
A Randomized Controlled Study Assessing Convalescent Immunoglobulins vs Convalescent Plasma for Hospitalized Patients With Coronavirus 2019
‪Yasmin Maor‬‏, Eilat Shinar, Marina Izak, et al.
Clinical Infectious Diseases (2023) Vol. 77, Iss. 7, pp. 964-971
Open Access | Times Cited: 10
Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2
Thierry Burnouf, Birgit Gathof, Evan M. Bloch, et al.
Transfusion Medicine Reviews (2022) Vol. 36, Iss. 3, pp. 125-132
Open Access | Times Cited: 12
Mortality rates among hospitalized patients with COVID-19 treated with convalescent plasma A Systematic review and meta-analysis
Jonathon W. Senefeld, Ellen K. Gorman, Patrick W. Johnson, et al.
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 7
Stepwise options for preparing therapeutic plasma proteins from domestic plasma in low‐ and middle‐income countries
Thierry Burnouf, Jay S. Epstein, Jean‐Claude Faber, et al.
Vox Sanguinis (2023) Vol. 119, Iss. 2, pp. 102-109
Open Access | Times Cited: 7
The effect of intravenous immunoglobulins on the outcomes of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Chih‐Cheng Lai, Wang‐Chun Chen, Ching-Yi Chen, et al.
Expert Review of Anti-infective Therapy (2022) Vol. 20, Iss. 10, pp. 1333-1340
Closed Access | Times Cited: 11
Safety and efficacy of COVID-19 hyperimmune globulin (HIG) solution in the treatment of active COVID-19 infection- Findings from a Prospective, Randomized, Controlled, Multi-Centric Trial
Devang Parikh, Alok Chaturvedi, Naman K. Shah, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 14
The outcome of using intravenous immunoglobulin (IVIG) in critically ill COVID-19 patients’: a retrospective, multi-centric cohort study
Mohammadreza Salehi, Mahdi Barkhori Mehni, Mohammadmehdi Akbarian, et al.
European journal of medical research (2022) Vol. 27, Iss. 1
Open Access | Times Cited: 10
Controversies about immunoglobulin replacement therapy in HSCT recipients with hypogammaglobulinemia
Akihiro Ohmoto, Shigeo Fuji, Kendall C. Shultes, et al.
Bone Marrow Transplantation (2022) Vol. 57, Iss. 6, pp. 874-880
Open Access | Times Cited: 10
Recent advances in passive immunotherapies for COVID-19: The Evidence-Based approaches and clinical trials
Pooya Farhangnia, Shiva Dehrouyeh, Amir Reza Safdarian, et al.
International Immunopharmacology (2022) Vol. 109, pp. 108786-108786
Open Access | Times Cited: 10
Comparative efficacy and safety of pharmacological interventions for severe COVID-19 patients: An updated network meta-analysis of 48 randomized controlled trials
Qinglin Cheng, Gang Zhao, Chen Jun-fang, et al.
Medicine (2022) Vol. 101, Iss. 41, pp. e30998-e30998
Open Access | Times Cited: 9
Heterologous Hyperimmune Polyclonal Antibodies Against SARS-CoV-2: A Broad Coverage, Affordable, and Scalable Potential Immunotherapy for COVID-19
Alberto Alape‐Girón, Andrés Moreira‐Soto, Mauricio Arguedas, et al.
Frontiers in Medicine (2021) Vol. 8
Open Access | Times Cited: 11
A role for Nucleocapsid-specific antibody function in Covid-19 Convalescent plasma therapy
Jonathan D. Herman, Chuangqi Wang, John S. Burke, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 8
The efficiency of convalescent plasma in COVID-19 patients: A systematic review and meta-analysis of randomized controlled clinical trials
Zhenbei Qian, Zhijin Zhang, Haomiao Ma, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 8
SARS‐CoV‐2 neutralising antibody therapies: Recent advances and future challenges
Mingtao Liu, Zhiman Liang, Zhangkai J. Cheng, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 5
Closed Access | Times Cited: 4
Page 1 - Next Page

Scroll to top